Avadel PharmaceuticalsAVDL
13F holders, Q3 2024 (September 30)5holders −5
0new positions
5sold out
$13.11avg. 13F price*
At the end of Q3 2024, 5 institutions reported holding Avadel Pharmaceuticals plc (AVDL) in their 13F filings, down 5 from Q2 2024. 0 opened new positions and 5 sold out. The largest holders were Knoll Capital Management, LLC ($7.9M), Knott David M Jr ($4.4M) and Schulhoff & Co. Inc. ($1.8M).
- Company
- Avadel Pharmaceuticals plc
- CUSIP
- 05337M104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 5 | $83.7M |
All 13F filers, Q2 2024 → Q3 2024: 5,955,013 shares sold, net −5,955,013 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Knoll Capital Management, LLC | 3.65% | No change | 600,000 | $7.9M |
| Knott David M Jr | 1.53% | Reduce -0.3% | 332,000 | $4.4M |
| Schulhoff & Co. Inc. | 0.75% | No change | 137,000 | $1.8M |
| 1620 Investment Advisors, Inc. | 0.01% | No change | 1,000 | $13K |
| Huntington National Bank | 0.00% | No change | 1 | $16 |
"% of holder's portfolio" is AVDL's weight in each manager's 13F, not the share of Avadel Pharmaceuticals plc the manager owns.